Background: MYC is a well-established cancer driver gene regulating the expression of numerous genes, indicating that polymorphisms in MYC response elements could affect tumorigenesis through altering MYC regulation. We performed integrative multistage study to evaluate the effects of variants in MYC response elements and colorectal cancer (CRC) risk.
Introduction
The c-Myc (MYC) gene is a well-established oncogene that functions as a pleiotropic transcription factor, and is estimated to bind to over 10% of genes in different cell types [1] . MYC can either activate or repress downstream genes via binding the consensus DNA element (5 0 -CACGTG-3 0 , also known as E-box) [2] , and thus plays essential roles in cell cycle progression, apoptosis and cellular transformation [3, 4] . The mutation, overexpression, rearrangement or translocation of this gene is associated with a variety of tumors, including colorectal cancer (CRC) [5, 6] . The MYC gene is located on human chromosome 8q24.21, which was one of the earliest identified CRC risk loci. The strongest risk SNP in this region, rs6983267, has been consistently replicated in multiple independent populations [7] [8] [9] [10] . Evidence has demonstrated that this variant exerts its function by directly or indirectly regulating the function or expression of MYC in in vivo and in vitro experiments [11] . The above evidence indicates that MYC is an important gene in CRC, and SNPs in MYC response elements may influence MYC binding affinity and affect the expression of its target genes, thus leading to differences among individuals in CRC susceptibility.
In this study, we systematically screened potential functional SNPs in MYC response elements, and carried out a two-stage case-control study to comprehensively evaluate the associations between these SNPs and the risk of CRC. We identified that rs11777210, located in an MYC response element, was significantly associated with CRC risk. Interestingly, we found a significant interaction between rs11777210 and rs6983267. A series of functional assays were further carried out to investigate the underlying mechanisms.
Methods

Selection of candidate SNPs in MYC response elements
An MYC chromatin immunoprecipitation sequencing (ChIP-Seq) dataset (GSM1242269) from the human CRC cell line LoVo was obtained from the NCBI GEO database. Six DNase I hypersensitive sites sequencing (DNase-Seq) datasets generated from the CRC cell lines HCT116 and Caco2 were downloaded from the ENCODE database. The overlapped regions were defined as active MYC binding regions. Next, we mapped the positions of SNPs (downloaded from dbSNP) to active MYC binding regions and limited the minimum allele frequency (MAF) of SNPs in Chinese population to !0.05. To narrow down the TF binding regions of interest, we further used MATCH software [12] based on the TRANSFAC matrix to predict MYC response elements in regions flanking candidate SNPs. SNPs whose one allele shows MYC binding but the other allele does not were defined as final candidate SNPs.
Case-control study and functional experiments
We studied a total of 4830 CRC cases and 4759 controls, including 769 cases and 849 controls in discovery stage and 4061 cases and 3910 controls in replication stage [13, 14] . The human CRC cell lines LoVo, SW480 and HCT15 were used for functional assays. Detailed information of study population, SNP genotyping and functional experiments are provided in supplementary methods (see also supplementary Table S1 , available at Annals of Oncology online).
Statistical analysis
Multivariable logistic regression analysis was used to assess the correlation between each SNP and CRC susceptibility. Per-allele odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated with adjustment for gender, age group, smoking status and drinking status. Gene-gene interactions were evaluated using a bootstrapping test of goodness-of-fit in Stata v11.0 [15] and multivariable logistic regression analysis adjusting for gender, age group, smoking status and drinking status.
The expression data calculated by RNA-Seq by Expectation Maximization (RSEM) of colon adenocarcinoma, rectum adenocarcinoma and other cancer types were downloaded from The Cancer Genome Atlas (TCGA) data portal. The paired Student's t-test was used to detect differential expression between tumor tissues and adjacent normal tissues. The Expression quantitative trait loci (eQTL) analysis was conducted as previously reported in Li et al. [16] .
Results
Genome-wide screening of candidate SNPs in MYC response elements
As shown in Figure 1A , we systematically screened the potentially functional SNPs in MYC response elements in the whole genome. We obtained 11 941 MYC binding peaks with an average length of 1490 bp from ChIP-Seq data. To select active regions, we mapped these MYC peaks to 389 948 DNase peaks from six DNase-Seq datasets, 4335 regions with an average length of 127 bp were defined as active binding regions. Using dbSNP information, 848 SNPs with MAF ! 0.05 were mapped to these regions. MYC typically recognizes E-box sequences [2] . We further used MATCH software [12] to predict MYC response elements in regions flanking candidate SNPs, and 12 SNPs (supplementary Table S2 , available at Annals of Oncology online) were predicted to have a potential impact on the MYC binding.
Rs11777210 is a novel CRC susceptibility locus in Han Chinese
To investigate the possible interactions between candidate SNPs in MYC response elements and the risk SNP near MYC found by other GWASs [7] [8] [9] [10] , we also genotyped the SNP rs6983267. Thus, 13 SNPs were genotyped in the discovery stage, and 5 positive SNPs were replicated in the following stage ( Figure 1B) . The demographic characteristics of the two stages are summarized in supplementary Table S3 , available at Annals of Oncology online.
In addition to the GWAS-identified risk SNP rs6983267, which remained significantly associated with CRC risk, we also found that another SNP, rs11777210 (T > C) in the first intron of KBTBD11, was significantly associated with CRC susceptibility in all genetic models [rs11777210: dominant model, OR(95%CI) ¼ 
Genetic interaction between rs6983267 and rs1177210
Genetic interaction analysis showed that there was a significant interaction between rs6983267 and rs11777210 in both the multiplicative interaction (P -combined ¼ 0.003), and additive interaction model (P -combined ¼ 0.005) ( Figure 1B , supplementary Table S6 , available at Annals of Oncology online). We further tested our hypothesis by stratified analysis to determine the joint genotypic effect for all combinations of rs6983267 and rs11777210 genotypes. We found that compared with those subjects without risk alleles at both loci (MYC TT, KBTBD11 TT), subjects carrying rs6983267 G allele and/or rs11777210 C allele exhibited higher CRC risk, and the OR was strongest in individuals homozygous for the risk alleles at both loci (MYC GG, KBTBD11 CC; OR -combined ¼ 2.83, P -combined ¼ 3.62 Â 10 À5 , Figure 1B ). Collectively, these results indicated that carriers of both MYC rs6983267 and KBTBD11 rs11777210 risk alleles have a higher genetic predisposition to CRC risk, which is likely due to the potential gene-gene interaction between MYC and KBTBD11 ( Figure 1C ).
Rs11777210 resulted in allele-specific differences in MYC binding affinity As rs1177210 was predicted to influence MYC binding, we firstly performed electrophoretic mobility shift assays (EMSAs) in LoVo and SW480 cells to examine whether it could affect the binding affinity of MYC. We found that the oligonucleotide probe containing the rs11777210 C allele exhibited stronger binding affinity to nuclear extracts than the probe containing the T allele ( Figure 2A and B, lane 2 versus lane 7). Furthermore, competition assays with unlabeled probes demonstrated that the addition of excess unlabeled probes containing the rs11777210 C allele gradually competed away the binding signal in a dose-dependent manner ( Figure 2A and B, lane 3 and lane 4), but unlabeled probes containing the rs11777210 T allele did not affect the binding activity of the C allele ( Figure 2A and B, lane 5). In addition, we performed a super-shift EMSA using an MYC antibody in LoVo and SW480 cells, and observed a super-shifted band when the MYC antibody and the rs11777210 C probe were incubated with nuclear cell extracts ( Figure 2C ). These findings demonstrated that rs11777210 could mediate allele-specific MYC binding in CRC cells.
Rs11777210 resulted in allelic-specific transcriptional activity
We further examined whether rs11777210 had an allele-specific effect on transcriptional activity using dual-luciferase reporter assays. We observed that the expression level of the construct containing rs11777210 C allele was significantly decreased by 40.0%, 42.1% and 33.1% compared with that of rs11777210 T allele construct in SW480, LoVo and HCT15 cells, respectively ( Figure 2D ). In our collected CRC adjacent normal tissues, we also found that the expression of KBTDB11 was significantly correlated with the genotype of rs11777210 (P ¼ 0.011). With an increase in the rs11777210 C risk allele, the average expression of KBTDB11 gradually decreased ( Figure 2E ). These results demonstrated that rs11777210 T > C could repress transcriptional activity.
The effect of rs11777210 on transcriptional activity mediated by MYC
To validate whether the effect of rs11777210 T > C on transcriptional activity is mediated by MYC, dual-luciferase reporter assays were further performed in SW480, LoVo and HCT15 cells, in which MYC expression was knocked down by siRNAs. Three siRNAs were designed to knock down the expression of MYC, and siRNA1 and siRNA2 can efficiently decreased the expression of MYC in a dose-dependent manner ( Figure 2F ). In LoVo, SW480 and HCT15 cells that were either mock transfected or transfected with an siRNA control, the expression level of the construct containing rs11777210 C allele was significantly lower than that of rs11777210 T allele construct ( Figure 2G and supplementary Figure S1A -C, available at Annals of Oncology online). When the MYC expression level was gradually decreased by siRNA interference, the repression of transcriptional activity caused by rs11777210 C was gradually rescued (P < 0.01), while the transcriptional activity of the construct with rs11777210 T was completely unaffected by the expression of MYC ( Figure 2G and supplementary Figure S1A -C, available at Annals of Oncology online). Collectively, these results confirmed that the effect of rs11777210 C on transcriptional activity was mediated by MYC.
Genotype dependence of negative correlation between the expression of MYC and KBTBD11
Given that rs11777210 is located in the first intron of KBTBD11, we hypothesized KBTBD11 was a causal target gene of MYC. We measured the endogenous KBTDB11 expression in SW480, LoVo cells (carrying heterozygous genotype at the rs11777210 site) and HCT15 (carrying genotype CC at the rs11777210 site) with different MYC concentrations and found that when the expression of MYC was gradually decreased by increasing the siRNA concentration, the expression of KBTBD11 gradually increased accordingly ( Figure 2F and H and supplementary Figure S1D , available at Annals of Oncology online) in a clear dose-dependent manner. Furthermore, we examined the expression relationship between MYC and KBTBD11 in TCGA CRC tissue samples ( Figure 2I-K) .
In TCGA dataset, we found that the expression of KBTBD11 was negatively correlated with that of MYC in individuals with the rs11777210 CC genotype (N ¼ 40, P ¼ 0.01, r ¼ -0.38; Figure 2I ), but not with other genotypes (Figure 2J and K). In our collected CRC adjacent normal tissues, we also found significantly negative correlation between MYC and KBTBD11 in individuals carrying rs11777210 C allele (N ¼ 25, P ¼ 0.04, r ¼ -0.41; supplementary Figure S2A , available at Annals of Oncology online). These results confirmed that MYC negatively regulated KBTBD11 in an rs11777210 genotype-dependent manner.
The potential role of KBTBD11 as a putative tumor suppressor gene
We compared the expression of KBTBD11 in 32 pairs of TCGA CRC tissue specimens and adjacent normal tissues, and observed that the KBTBD11 expression level was significantly lower in tumors than in adjacent normal tissues (average 645 RSEM in tumor versus 1497 RSEM in adjacent normal tissues, Figure 3A) . Similar trends were also found in several other TCGA cancer types (P < 0.001, Figure 3A) , suggesting that KBTBD11 may function as a putative tumor suppressor gene in carcinogenesis.
We next investigated the impact of KBTBD11 on CRC cell growth by overexpression or silencing of KBTBD11 (supplementary Figure S2B , available at Annals of Oncology online). In SW480, LoVo and HCT15 cells, we observed that elevated KBTBD11 expression significantly suppressed cell growth (P < 0.05, Figure 3B ). Conversely, decreasing KBTBD11 expression by siRNAs promoted cell growth in the three CRC cell lines (P < 0.05, Figure 3C) . The cell apoptosis assays demonstrated that overexpression of KBTBD11 promoted cell apoptosis in the three CRC cell lines, whereas knockdown of KBTBD11 inhabited cell apoptosis (Figure 3D ).
Rs6983267 G allele is associated with higher MYC expression
As expected, we observed that MYC expression was significantly increased in TCGA CRC tumor tissues compared with adjacent normal tissues (tumor/normal fold change ¼ 3.61, Figure 3E ), which confirmed its role as an oncogene in CRC. Because previous results of the correlation between MYC expression and rs6983267 genotypes in different populations were not always consistent, we further examined the correlation between MYC expression and rs6983267 genotypes in TCGA CRC tissues and our collected CRC adjacent normal tissues. We observed that the expression of MYC was significantly correlated with the genotype of rs6983267 in tumor tissues (P ¼ 0.015, Figure 3F ) and normal tissues (P ¼ 0.0006, supplementary Figure S2D , available at Annals of Oncology online). With an increase in the rs6983267 G risk allele, the average expression of MYC gradually increased (average expression: TT, 4404 RSEM; GT, 5015 RSEM; GG 5659 RSEM, Figure 3F ).
Discussion
Through multidisciplinary approaches including bioinformatics, genetic studies and functional assays, we identified a novel SNP, rs11777210, in KBTBD11 significantly associated with CRC risk. KBTBD11, which shows a high degree of conservation among species and belongs to the BTB-kelch gene family, has not yet been fully studied [17] . TCGA expression data showed that KBTBD11 expression was significantly decreased in tumor tissues compared with adjacent normal portion of CRC. Moreover, we demonstrated that KBTBD11 knockdown promoted CRC cell proliferation, while overexpression of KBTBD11 inhibited cell growth in two CRC cell lines. In the GenomeRNAi database [18] , a large scale siRNA screening study (http://www.genomernai. org/v16/singleExpPhenotypes/GR00215-A) indicated that KBTBD11 was a candidate MYC-synthetic lethal gene [19] , and another siRNA screening study showed that knockdown of KBTBD11 increased cell death of HMEC cells [20] . The evidence above demonstrated that KBTBD11 play an important role in tumorigenesis and function as a putative tumor suppressor gene.
One of the important strengths of the current study is the identification of an interaction between rs6983267 and rs11777210 both in population and biological mechanism study. We firstly observed a significant interaction of these two SNPs in population. Rs6983267 is near MYC and rs11777210 is in KBTBD11, thus we hypothesized the interaction could be mediated by MYC-KBTBD11 interplay. The eQTL analysis showed that the rs6983267 G allele could up-regulate MYC expression. The ChIPSeq and EMSA showed that MYC can bind with KBTBD11 rs11777210 around region, while dual-luciferase reporter assays in vitro and expression data in tissues demonstrated that MYC could repress the expression of KBTBD11 when the rs11777210 C risk allele was present. MYC is a well-established oncogene, and KBTDB11 functions as a putative tumor suppressor gene. Collectively, the MYC-KBTBD11 interplay could possibly explain the phenomenon that carriers of at least one copy of the risk alleles at both loci exhibited a higher CRC risk compared with those subjects without risk alleles at both loci, and the OR was strongest in homozygous individuals carrying the risk alleles at both loci. However, further biological experiments are needed to fully elucidate the downstream pathway of MYC-KBTBD11 tumorigenesis.
Conclusion
In conclusion, we identified a novel susceptibility locus and a novel target gene for CRC and observed a significant interaction between rs11777210 and rs6983267. Our results highlighted the high CRC risk of people carrying rs6983267 G and rs11777210 C alleles, and provided possible biological mechanism of the interaction.
boxplots, the horizontal line indicates the median, the box indicates the first to third quartile of expression, and each dot represents the expression of a sample. (F) The expression of MYC and KBTBD11 in SW480 transfected with different doses of MYC siRNAs (siMYC-1, siMYC-2). (G) Relative luciferase activity of constructs containing either the rs11777210 C or rs11777210 T allele transfected with different doses of siMYC-1 in SW480 cells. Relative luciferase activity was calculated by normalizing the firefly/Renilla luciferase activity of the construct containing the rs11777210 C or T allele to that of the empty pGL-3 vector. The line chart compares the slope difference between the constructs containing rs11777210 T and rs11777210 C in cells transfected with different amounts of siMYC-1. (H) The expression of KBTBD11 in SW480 transfected with different doses of MYC siRNAs (siMYC-1, siMYC-2). All experiments were carried out in triplicate, each with at least three technical replicates. The data are shown as the mean 6 SD from three independent experiments. *P < 0.05; **P < 0.01, compared with the construct containing the rs11777210 T allele or the siControl group using Student's t-test. (I-K) The expression correlation between MYC and KBTBD11 using TCGA CRC genotype and expression data. The expression of KBTBD11 was negatively correlated with that of MYC in individuals with the rs11777210 CC genotype (I), but not with other genotypes (J and K). All P values were calculated using Pearson's correlation analysis. Overexpression of KBTBD11 promoted cell apoptosis, whereas knockdown of KBTBD11 inhibited cell apoptosis. All experiments were carried out in triplicate, each with at least three technical replicates. The data are shown as the mean 6 SEM from three independent experiments. *P < 0.05, compared with the pcDNA3.1 (þ) empty vector control or the siControl group using Student's t-test. (E) The expression of MYC was higher in CRC tumor tissues than in adjacent normal tissues. (F) The association between rs6983267 genotypes and MYC expression. In the boxplots, the horizontal line indicates the median, the box indicates the first to third quartile of expression, and each dot represents the expression of a sample. The P value was calculated using the linear regression model.
